209 related articles for article (PubMed ID: 17571952)
1. Chemoprevention of rat prostate carcinogenesis by soy isoflavones and by Bowman-Birk inhibitor.
McCormick DL; Johnson WD; Bosland MC; Lubet RA; Steele VE
Nutr Cancer; 2007; 57(2):184-93. PubMed ID: 17571952
[TBL] [Abstract][Full Text] [Related]
2. Oncogenicity evaluations of chemopreventive soy components in p53((+/-)) (p53 knockout) mice.
Johnson WD; Dooley L; Morrissey RL; Arp L; Kapetanovic I; Crowell JA; McCormick DL
Int J Toxicol; 2006; 25(3):219-28. PubMed ID: 16717037
[TBL] [Abstract][Full Text] [Related]
3. Chemoprevention of rat prostate carcinogenesis by early and delayed administration of dehydroepiandrosterone.
Rao KV; Johnson WD; Bosland MC; Lubet RA; Steele VE; Kelloff GJ; McCormick DL
Cancer Res; 1999 Jul; 59(13):3084-9. PubMed ID: 10397249
[TBL] [Abstract][Full Text] [Related]
4. Effects of Bowman-Birk inhibitor on rat colon carcinogenesis.
Kennedy AR; Billings PC; Wan XS; Newberne PM
Nutr Cancer; 2002; 43(2):174-86. PubMed ID: 12588698
[TBL] [Abstract][Full Text] [Related]
5. Null effect of dietary restriction on prostate carcinogenesis in the Wistar-Unilever rat.
McCormick DL; Johnson WD; Haryu TM; Bosland MC; Lubet RA; Steele VE
Nutr Cancer; 2007; 57(2):194-200. PubMed ID: 17571953
[TBL] [Abstract][Full Text] [Related]
6. Influence of N-methyl-N-nitrosourea, testosterone, and N-(4-hydroxyphenyl)-all-trans-retinamide on prostate cancer induction in Wistar-Unilever rats.
McCormick DL; Rao KV; Dooley L; Steele VE; Lubet RA; Kelloff GJ; Bosland MC
Cancer Res; 1998 Aug; 58(15):3282-8. PubMed ID: 9699656
[TBL] [Abstract][Full Text] [Related]
7. Preparation and production of a cancer chemopreventive agent, Bowman-Birk inhibitor concentrate.
Kennedy AR; Szuhaj BF; Newberne PM; Billings PC
Nutr Cancer; 1993; 19(3):281-302. PubMed ID: 8346077
[TBL] [Abstract][Full Text] [Related]
8. Reproductive toxicity assessment of chronic dietary exposure to soy isoflavones in male rats.
Faqi AS; Johnson WD; Morrissey RL; McCormick DL
Reprod Toxicol; 2004 Jun; 18(4):605-11. PubMed ID: 15135855
[TBL] [Abstract][Full Text] [Related]
9. Detection of Bowman-Birk inhibitor and anti-Bowman-Birk inhibitor antibodies in sera of humans and animals treated with Bowman-Birk inhibitor concentrate.
Wan XS; Serota DG; Ware JH; Crowell JA; Kennedy AR
Nutr Cancer; 2002; 43(2):167-73. PubMed ID: 12588697
[TBL] [Abstract][Full Text] [Related]
10. Chemoprevention of rat prostate carcinogenesis by 9-cis-retinoic acid.
McCormick DL; Rao KV; Steele VE; Lubet RA; Kelloff GJ; Bosland MC
Cancer Res; 1999 Feb; 59(3):521-4. PubMed ID: 9973192
[TBL] [Abstract][Full Text] [Related]
11. Influence of isoflavones in soy protein isolates on development of induced prostate-related cancers in L-W rats.
Pollard M; Luckert PH
Nutr Cancer; 1997; 28(1):41-5. PubMed ID: 9200149
[TBL] [Abstract][Full Text] [Related]
12. Induction of apoptosis in the LNCaP human prostate carcinoma cell line and prostate adenocarcinomas of SV40T antigen transgenic rats by the Bowman-Birk inhibitor.
Tang M; Asamoto M; Ogawa K; Naiki-Ito A; Sato S; Takahashi S; Shirai T
Pathol Int; 2009 Nov; 59(11):790-6. PubMed ID: 19883429
[TBL] [Abstract][Full Text] [Related]
13. Effects of Bowman-Birk inhibitor concentrate (BBIC) in patients with benign prostatic hyperplasia.
Malkowicz SB; McKenna WG; Vaughn DJ; Wan XS; Propert KJ; Rockwell K; Marks SH; Wein AJ; Kennedy AR
Prostate; 2001 Jun; 48(1):16-28. PubMed ID: 11391683
[TBL] [Abstract][Full Text] [Related]
14. Dietary prevention of hormone refractory prostate cancer in Lobund-Wistar rats: a review of studies in a relevant animal model.
Pollard M; Suckow MA
Comp Med; 2006 Dec; 56(6):461-7. PubMed ID: 17219775
[TBL] [Abstract][Full Text] [Related]
15. Suppression of carcinogenesis in the intestines of min mice by the soybean-derived Bowman-Birk inhibitor.
Kennedy AR; Beazer-Barclay Y; Kinzler KW; Newberne PM
Cancer Res; 1996 Feb; 56(4):679-82. PubMed ID: 8630994
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of N-methyl-N-nitrosourea-induced mammary tumors in rats by the soybean isoflavones.
Constantinou AI; Mehta RG; Vaughan A
Anticancer Res; 1996; 16(6A):3293-8. PubMed ID: 9042303
[TBL] [Abstract][Full Text] [Related]
17. Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial.
Armstrong WB; Kennedy AR; Wan XS; Taylor TH; Nguyen QA; Jensen J; Thompson W; Lagerberg W; Meyskens FL
Clin Cancer Res; 2000 Dec; 6(12):4684-91. PubMed ID: 11156220
[TBL] [Abstract][Full Text] [Related]
18. Induction of dorsolateral prostate adenocarcinomas and other accessory sex gland lesions in male Wistar rats by a single administration of N-methyl-N-nitrosourea, 7,12-dimethylbenz(a)anthracene, and 3,2'-dimethyl-4-aminobiphenyl after sequential treatment with cyproterone acetate and testosterone propionate.
Bosland MC; Prinsen MK
Cancer Res; 1990 Feb; 50(3):691-9. PubMed ID: 2137026
[TBL] [Abstract][Full Text] [Related]
19. Effect of the Bowman-Birk inhibitor (a soy protein) on in vitro bladder neck/urethral and penile corporal smooth muscle activity.
Malkowicz SB; Liu SP; Broderick GA; Wein AJ; Kennedy AR; Levin RM
Neurourol Urodyn; 2003; 22(1):54-7. PubMed ID: 12478602
[TBL] [Abstract][Full Text] [Related]
20. Prevention of induced prostate-related cancer by soy protein isolate/isoflavone-supplemented diet in Lobund-Wistar rats.
Pollard M; Wolter W; Sun L
In Vivo; 2000; 14(3):389-92. PubMed ID: 10904871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
